Greenleaf Trust grew its stake in Sanofi SA (NYSE:SNY) by 67.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,062 shares of the company’s stock after acquiring an additional 10,858 shares during the quarter. Greenleaf Trust’s holdings in Sanofi were worth $1,175,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in SNY. Essex Savings Bank bought a new position in shares of Sanofi during the fourth quarter valued at $30,000. Lavaca Capital LLC bought a new position in shares of Sanofi during the fourth quarter valued at $51,000. Focused Wealth Management Inc lifted its holdings in shares of Sanofi by 33.2% during the fourth quarter. Focused Wealth Management Inc now owns 1,204 shares of the company’s stock valued at $52,000 after purchasing an additional 300 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Sanofi by 48.1% during the fourth quarter. Parallel Advisors LLC now owns 1,760 shares of the company’s stock valued at $76,000 after purchasing an additional 572 shares in the last quarter. Finally, Whitener Capital Management Inc. lifted its holdings in shares of Sanofi by 71.5% during the fourth quarter. Whitener Capital Management Inc. now owns 2,000 shares of the company’s stock valued at $86,000 after purchasing an additional 834 shares in the last quarter. 7.04% of the stock is currently owned by institutional investors and hedge funds.
SNY stock opened at $42.15 on Thursday. Sanofi SA has a fifty-two week low of $37.43 and a fifty-two week high of $45.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The stock has a market capitalization of $105.72 billion, a price-to-earnings ratio of 13.47, a PEG ratio of 2.41 and a beta of 0.67.
Sanofi (NYSE:SNY) last posted its earnings results on Thursday, February 7th. The company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company had revenue of $9 billion for the quarter, compared to the consensus estimate of $9 billion. During the same quarter in the prior year, the company earned $1.06 earnings per share. Sanofi’s revenue was up 3.5% on a year-over-year basis. On average, equities analysts predict that Sanofi SA will post 3.1 earnings per share for the current year.
A number of research analysts have recently issued reports on SNY shares. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Friday, January 18th. Jefferies Financial Group raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Argus upped their price target on Sanofi from $48.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, November 8th. TheStreet downgraded Sanofi from a “b” rating to a “c+” rating in a report on Thursday, February 7th. Finally, Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a report on Thursday, November 1st. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and an average target price of $51.00.
ILLEGAL ACTIVITY NOTICE: This news story was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thelincolnianonline.com/2019/02/21/greenleaf-trust-has-1-18-million-holdings-in-sanofi-sa-sny.html.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Cash Flow
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.